| HHS Letter to COVID-19 therapeutics manufacturers, distributors, pharmacies and the health care payer community. |
| Saturday, November 04, 2023 04:25 PM |
| The COVID-19 response remains a significant public health priority for the Biden-Harris Administration. People are still at risk of infection and re-infection, and millions are experiencing the longer-term effects of the virus. Read more. |